Regulus Therapeutics (NASDAQ:RGLS) Research Coverage Started at StockNews.com theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
HC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
HC Wainwright reiterated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a research report released on Monday morning, Benzinga reports. The brokerage currently has a $9.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Regulus Therapeutics’ Q1 2024 earnings at ($0.19) EPS, Q2 2024 earnings […]
Regulus Therapeutics Inc. (NASDAQ:RGLS – Get Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 5,130,000 shares, an increase of 9,244.3% from the February 29th total of 54,900 shares. Based on an average daily volume of 2,870,000 shares, the days-to-cover ratio is currently 1.8 […]
StockNews.com initiated coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a research report report published on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock. RGLS has been the subject of a number of other reports. Leerink Partnrs reaffirmed an outperform rating on shares of Regulus Therapeutics in a […]